Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UNGS has had a nice strong movement to the upside lately
Mon, 23 Sep 2013 13:00:00 GMT ~ IGEX Information to Be Available Through S&P Capital IQ's Market Access Program
[Marketwired] - Indo Global Exchange Pte., Ltd. , a company operating in the Asian financial services sector announced today that its company information will be made available via S&P Capital IQ's Market Access Program, ...
read full: http://finance.yahoo.com/news/igex-information-available-p-capital-130000936.html $IGEX
Wed, 18 Sep 2013 17:56:03 GMT ~Forer IGEX D. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements
read full: http://biz.yahoo.com/e/130918/igex8-k.html IGEX
Mon, 16 Sep 2013 13:00:00 GMT ~ IGEX Appoints Asian Financial Markets Veteran Dermot M. Monaghan to Board
[Marketwired] - Indo Global Exchange Pte, Ltd. , an early entrant into the Indonesian financial market services sector, is pleased to announce and welcome the appointment of Mr. Dermot Michael Monaghan to its Board of ...
read full: http://finance.yahoo.com/news/igex-appoints-asian-financial-markets-130000871.html
Keeping a close eye on IGEX today
$IGEX on watch here
HPNN's goal is to provide the best products and greatest services possible while remaining focused on the bottom line for the company and our shareholders.
HPNN Contact Info
2222 Michelson Drive
Suite 222-182
Irvine, CA 92612
Website: http://www.hop-on.com
Phone: 1-949-756-9008
Email: contact@hop-on.com
HPNN Press Releases:
http://finance.yahoo.com/q/h?s=HPNN+Headlines
Tue, 26 Mar 2013 17:22:00 GMT ~ Hop-on - Newly Designed Electronic Cigarettes and Cigars to More Effectively Quit Smoking, and New Nicotine Substitutes
[PR Newswire] - TEMECULA, Calif., March 26, 2013 /PRNewswire/ -- Hop-on, Inc. (OTC Pink: HPNN) and USAcig, Inc. announced today that after much research and development, consumer trials, and coordination with medical ...
read full: http://finance.yahoo.com/news/hop-newly-designed-electronic-cigarettes-172200035.html
Mon, 30 Sep 2013 13:00:00 GMT ~ IGEX Launches Affiliate Relationship With Leading Pacific Rim Research, Education and Trading Partner
[Marketwired] - Indo Global Exchange Pte., Ltd. , a company operating in the Asian financial services sector, today confirmed its entry into a regionally exclusive affiliate partner arrangement with leading Pacific Rim ...
read full: http://finance.yahoo.com/news/igex-launches-affiliate-relationship-leading-130000227.html IGEX
Wed, 25 Sep 2013 19:46:52 GMT ~ INDO GLOBAL EXCHANGE(S) PTE, LTD. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistere
read full: http://biz.yahoo.com/e/130925/igex8-k.html IGEX
Mon, 23 Sep 2013 13:00:00 GMT ~ IGEX Information to Be Available Through S&P Capital IQ's Market Access Program
[Marketwired] - Indo Global Exchange Pte., Ltd. , a company operating in the Asian financial services sector announced today that its company information will be made available via S&P Capital IQ's Market Access Program, ...
read full: http://finance.yahoo.com/news/igex-information-available-p-capital-130000936.html $IGEX
Wed, 18 Sep 2013 17:56:03 GMT ~ INDO GLOBAL EXCHANGE(S) PTE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements
read full: http://biz.yahoo.com/e/130918/igex8-k.html IGEX
Mon, 16 Sep 2013 13:00:00 GMT ~ IGEX Appoints Asian Financial Markets Veteran Dermot M. Monaghan to Board
[Marketwired] - Indo Global Exchange Pte, Ltd. , an early entrant into the Indonesian financial market services sector, is pleased to announce and welcome the appointment of Mr. Dermot Michael Monaghan to its Board of ...
read full: http://finance.yahoo.com/news/igex-appoints-asian-financial-markets-130000871.html
hey good morning folks. there is a lot of good $IGEX dd here
Hi there. Thanks for the HPNN news links
Very, very nice. I have PHNN on the radar here
Hey, good evening HPNN Fri, 09 Aug 2013 17:17:50 GMT ~ HOP-ON, INC. Financials
read full: http://finance.yahoo.com/q/is?s=hpnn
******************************
$NVLX Another apparent advantage for Nuvilex's treatment compared to the ABRAXANE-gemcitabine combination concerns the side effects (toxicities) associated with both treatments. Significant and severe drug-associated toxicities were seen with the ABRAXANE-gemcitabine combination, whereas with Nuvilex's treatment, side effects were essentially non-existent. The lack of side effects from live-cell encapsulation-ifosfamide combination is undoubtedly related to the low dose of ifosfamide used.
Another apparent advantage for Nuvilex's treatment compared to the ABRAXANE-gemcitabine combination concerns the side effects (toxicities) associated with both treatments. Significant and severe drug-associated toxicities were seen with the ABRAXANE-gemcitabine combination, whereas with Nuvilex's treatment, side effects were essentially non-existent. The lack of side effects from live-cell encapsulation-ifosfamide combination is undoubtedly related to the low dose of ifosfamide used.
$NVLX Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the ABRAXANE-gemcitabine combination. The results included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the ABRAXANE-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II trials for advanced, inoperable pancreatic cancer.
$NVLX Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the ABRAXANE-gemcitabine combination. The results included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the ABRAXANE-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II trials for advanced, inoperable pancreatic cancer.
$NVLX By comparison, two independent Phase II clinical trials revealed that Nuvilex's pancreatic cancer treatment, namely the combination of tiny capsules containing live drug-activating cells together with the single cancer drug ifosfamide (used for many years to treat a variety of cancers), helped patients to a far better outcome than that previously reported with standard single-drug gemcitabine and even that reported for the just approved ABRAXANE-gemcitabine combination.
$NVLX By comparison, two independent Phase II clinical trials revealed that Nuvilex's pancreatic cancer treatment, namely the combination of tiny capsules containing live drug-activating cells together with the single cancer drug ifosfamide (used for many years to treat a variety of cancers), helped patients to a far better outcome than that previously reported with standard single-drug gemcitabine and even that reported for the just approved ABRAXANE-gemcitabine combination.
$NVLX ABRAXANE is a form of the chemotherapy drug paclitaxel (TAXOL®) that has been modified by the addition of a human protein called albumin. The combination of ABRAXANE with gemcitabine, improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone during the phase III clinical trial. Also, Celgene's results showed that the ABRAXANE-gemcitabine combination gave a 59% increase in one-year survival rate over that seen with gemcitabine alone.
$NVLX ABRAXANE is a form of the chemotherapy drug paclitaxel (TAXOL®) that has been modified by the addition of a human protein called albumin. The combination of ABRAXANE with gemcitabine, improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone during the phase III clinical trial. Also, Celgene's results showed that the ABRAXANE-gemcitabine combination gave a 59% increase in one-year survival rate over that seen with gemcitabine alone.
What should get shareholders of Nuvilex excited about the company's future is the actual data the FDA used to quickly approve the ABRAXANE-gemcitabine combination for pancreatic cancer. $NVLX
What should get shareholders of Nuvilex excited about the company's future is the actual data the FDA used to quickly approve the ABRAXANE-gemcitabine combination for pancreatic cancer. $NVLX
John Sofarnos, Managing Director of the Australian Stock Report states, "We are enthusiastic about our affiliate agreement with IGEX because we believe the Asian market has enormous growth potential for the development of new product and service opportunities aimed at ensuring customers can discover the benefits of investing in globally listed shares, CFDs and Foreign Exchange markets."
As a result of the agreement, IGEX can now offer several levels of services for self-directed clients, including a subscription service that delivers strategic trading information for self-execution, a signal service providing strategic information that the client can use to instruct the IGEX affiliate to execute on their account, and a power of attorney service where trading is managed on the clients behalf.
IGEX President and CEO Mr. John O'Shea states," We are very pleased to have ASR onboard as a primary service provider. We have committed to a significant marketing effort for the coming months ahead, and will be offering our clients excellent pricing across a variety of products including Foreign Exchange, CFDs, Stocks, and Managed Funds. To-date, the Asian marketplace has been largely underserviced for the needs of a rapidly growing retail consumer marketplace, and we are enthusiastic about introducing ASR as just the first of many future partners we intend to offer. Our aim is to aggregate, grow and deliver a comprehensive suite of specialty financial services directly focused on this emerging target audience."
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov.
About IGEX (OTCQB: IGEX)
IGEX is positioning itself at the forefront of the Asian financial market service sector through the support of partner relationships with noteworthy licensed suppliers of sophisticated global trading platforms in Equities, CFDs, Derivatives, Commodities, Energies, Foreign Exchange and Options. IGEXs world-class partners offer clients security and 100% transparency, which is critical for entry into this vast and virtually untapped Pacific Rim marketplace. For more information about our business, mission and strategic partners visit: www.igex.com.
About Australian Stock Report (ASR)
Australian Stock Report (ASR) is a sector-leading regional stock market research, education and trading organization. ASR strives to provide quality, unbiased and independent financial market research, guidance, education and solutions to its members. ASR's experience shows that if clients are served effectively, success will follow. ASR's team of market analysts and traders have been assembled based upon their considerable knowledge, accredited education, real-time market experience and ability to help those interested in learning more about financial markets. The Research and Education Teams are responsible for creating and maintaining subscription based research reports and world class educational workshops. For more information visit: www.australianstockreport.com.au.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing a new business and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and development plans, potential competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
On Behalf of the Board,
John F. O'Shea, President & CEO
Indo Global Exchange(s) Pte, Ltd. (IGEX)
Contact:
IGEX Investor Relations
Phone: + (011) 62 812 1318 37444
Email: investors@igex.com
Web: www.igex.com
$IGEX
$NVLX The FDA approval of the ABRAXANE-gemcitabine combination is the first new treatment to be approved for adenocarcinoma of the pancreas in nearly eight years and now replaces the gemcitabine-TARCEVA (erlotinib) combination, which was approved in 2005, as first-line therapy. Prior to that latter approval, single-agent gemcitabine, also known as GEMZAR®, had been the treatment of choice (the "gold standard") for the disease since its approval by the FDA in 1996.
$NVLX The FDA approval of the ABRAXANE-gemcitabine combination is the first new treatment to be approved for adenocarcinoma of the pancreas in nearly eight years and now replaces the gemcitabine-TARCEVA (erlotinib) combination, which was approved in 2005, as first-line therapy. Prior to that latter approval, single-agent gemcitabine, also known as GEMZAR®, had been the treatment of choice (the "gold standard") for the disease since its approval by the FDA in 1996.
Let's keep a close eye on $IGEX today
ASR is a subscription-based organization which provides unbiased and independent financial market research, guidance, education, and trading platform to its members. Located in Australia, the company offers high quality, dedicated financial products serving the needs of a broad and increasingly active consumer base. ASR reaches out to new retail customers in the emerging Asian market who typically appreciate educational assistance and support for their trading activities. $IGEX